Endothelin 1 and selectivity of endothelin receptor antagonists: To B or not to B?;Endothéline 1 et sélectivité des antagonistes des récepteurs de l'endothéline 1 : to B or not to B ?

Revue de Medecine Interne

Volumn 29, Issue 4, 2008, Pages 263-268

  Marie, I ^a   Bekri, S ^a   Levesque H ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Endothelin 1; ETA receptor; ETB receptor; Selectivity of endothelin 1 receptor antagonists; Sitaxsentan

Indexed keywords

AMBRISENTAN; ATRASENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENRASENTAN; SITAXSENTAN; TEZOSENTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEART FAILURE; HUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION;

ENDOTHELIN-1; HUMANS; ISOXAZOLES; MOLECULAR STRUCTURE; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 41149100981     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.01.001     Document Type: Article

References (50)

1. Hickey K.A., Rubanyi G., Paul R.J., and Highsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248 5 Pt 1 (1985) C550-C556
2. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
3. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H., and Schäfers H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 (2002) 1034-1036
4. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86 (1989) 2863-2867
5. Lüscher T.F., and Barton M. Endothelins and endothelin recptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102 (2000) 2434-2440
6. Saida K., Mitsui Y., and Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family: molecular cloning, expression, and biological activity. J Biol Chem 264 (1989) 14613-14616
7. Kloog Y., Ambar I., Sokolovsky M., Kochva E., Wollberg Z., and Bdolah A. Sarafotoxin, a novel vasoconstrictor peptdide: phosphoinositide hydrolysis in rat heart and brain. Science 242 (1988) 268-270
8. Schiffrin E.L. Role of endothelin-1 in hypertension. Hypertension 34 (1999) 876-881
9. Attina T., Camidge R., Newby D.E., and Webb D.J. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91 (2005) 825-831
10. Barst R.J. Sitaxsentan: a selective endothelin - A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 8 (2007) 95-109
11. Shi-Wen X., Denton C.P., Dashwood M.R., Holmes A.M., Bou-Gharios G., Pearson J.D., et al. Fibroblast matrix gene expression and connective tissue remodelling: role of endothelin-1. J Invest Dermatol 116 (2001) 417-425
12. Takuwa N., Takuwa Y., Yanagisawa M., Yamashita K., and Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover inI Swiss 3T3 fibroblasts. J Biol Chem 264 (1989) 7856-7861
13. Shi-Wen X., Chen Y., Denton C.P., Eastwood M., Renzoni E.A., Bou-Gharios G., et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15 (2004) 2707-2719
14. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 Suppl. 1 (2004) 13S-24S
15. Jankov R.P., Kantores C., Belcastro R., Yi M., and Tanswell A.K. Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr Res 60 (2006) 245-251
16. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 28 (2007) 117-125
17. Montani D., Jaïs X., Sitbon O., Capron F., Simonneau G., and Humbert M. Hypertension artérielle pulmonaire. Rev Mal Respir 22 (2005) 651-666
18. Cacoub P., Dorent R., Nataf P., Carayon A., Riquet M., Noe E., et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33 (1997) 196-200
19. De Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85 (1988) 9797-9800
20. Dupuis J., Cernacek P., Tardif J.C., Stewart D.J., Gosselin G., Dyrda I., et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135 (1998) 614-620
21. Dupuis J., Stewart D.J., Cernacek P., and Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94 (1996) 1578-1584
22. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
23. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
24. Cacoub P., Dorent R., Nataf P., and Carayon A. Endothelin-1 in pulmonary hypertension. N Engl J Med 329 (1993) 1967-1968
25. Langleben D., Dupuis J., Langleben I., Hirsch A.M., Baron M., Senécal J.L., et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129 (2006) 689-695
26. Yoshibayashi M., Nishioka K., Nakao K., Saito Y., Matsumura M., Ueda T., et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84 (1991) 2280-2285
27. Arai H., Hori S., Aramori I., Okhubo H., and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
28. A inhibition?. Curr Med Res Opin 22 (2006) 2567-2574
29. Sakurai T., Yanagisawa M., Takuwat Y., Miyazakit H., Kimura S., Goto K., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990) 732-735
30. A receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: a tyrosine kinase independent pathway. Br J Pharmacol 127 (1999) 153-160
31. B receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 104 (2003) 143-151
32. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165 (2002) 398-405
33. Hirata Y., Emori T., Eguchi S., Kanno K., Imai T., Ohta K., et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91 (1993) 1367-1373
34. A receptor antagonist. Pulm Pharmacol Ther 13 (2000) 87-97
35. Verhaar M.C., Strachan F.E., Newby D.E., Cruden N.L., Koomans H.A., Rabelink T.J., et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97 (1998) 752-756
36. Ivy D.D., McMurtry I.F., Yanagisawa M., Gariepy C.E., Le Cras T.D., Gebb S.A., et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 280 (2001) L1040-L1048
37. Fishman A.P. Clinical classification of pulmonary hypertension. Clin Chest Med 22 (2001) 385-391
38. B receptors. J Appl Physiol 81 (1996) 1510-1515
39. Opitz C.F., and Ewert R. Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest 36 suppl 3 (2006) 1-9
40. Cacoub P, Amoura Z, Langleben D. La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008. Rev Med Intern, sous presse.
41. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxentan. J Am Coll Cardiol 47 (2006) 2049-2056
42. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., et al. Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
43. Barst R.J., McGoon M., McLaughlin V., Tapson V., Rich S., Rubin L., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
44. Barst R.J., Rich S., Widlitz A., Hom E.M., McLaughlin V., and McFarlin J. Clinical efficacy of sitaxentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 121 (2002) 1860-1868
45. Benza R., Frost A., and Girgis R. Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan. Proc Am Thorac Soc 3 (2006) A729
46. Benza R., Mehta S., and Keogh A. Sitaxentan treatment for patients with pulmonary arterial hypertension failing bosentan treatment. Proc Am Thorac Soc 2 (2005) A201
47. Langleben D., Hirsch A.M., Shalit E., Lesenko L., and Barst R.J. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxentan, in patients with pulmonary arterial hypertension. Chest 126 (2004) 1377-1381
48. Pulido T., Kurzyna M., and Souza R. Sitaxentan 100 mg proves more effective than sitaxentan 50 mg in patients with pulmonary arterial hypertension. Proc Am Thorac Soc 3 (2006) A417
49. Girgis R.E., Frost A.E., Hill N.S., Horn E.M., Langleben D., McLaughlin V.V., et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 66 (2007) 1467-1472
50. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long term benefit?. Ann Med 35 (2003) 605-613